Sunshine Biopharma Inc (SBFM) — Titan Protect Analysis

SBFM

Sunshine Biopharma Inc

Healthcare · ·

$2.46

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$43M

Total market value of the company

Trailing P/E

N/A

Forward P/E

0.01

Based on estimated future earnings — lower means cheaper

Rev Growth

-9.1%

Year-over-year revenue change

Profit Margin

-17.0%

How much profit the company keeps from each dollar of revenue

ROE

-27.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$56.00

+2176% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 1 analysts covering this stock

About Sunshine Biopharma Inc

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium

https://sunshinebiopharma.com

Country: United States Employees: 50 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.962

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.1561

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.862

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-84.4%

Historical annualised return based on price data

Max Drawdown

-97.9%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$24.30

90% below the year high

52W Low

$2.11

17% above the year low

Avg Volume

1,529,685

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-12.50

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.46

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

33.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-17.3%

Profit from core operations before interest and tax

Free Cash Flow

$-4,710,076

Negative — the business is spending more than it generates

Revenue (TTM)

$35M

Total revenue over the last 12 months

Net Income

$-6,039,450

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$56.00

Target Median

$56.00

Target Low

$56.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go